Statistics

Total Visits

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy8

Select a period of time:

Number of views in the range

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy7

Views

Views
May 20243
June 20241
July 20242
August 20240
September 20240
October 20240
November 20241
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
United Kingdom1
 

Top cities views

Views
Chicago1
Prineville1